PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

OIPE
FEB 0 2 2004
PATENT & TRADEMARK OFFICE

Application Number	10/672,302
Filing Date	September 26, 2003
First Named Inventor	Hong Jin
Group Art Unit	1648
Examiner Name	Unassigned
Total Number of Pages in This Submission	
Attorney Docket Number	26-000320US

ENCLOSURES (check all that apply)

- [ ] Fee Transmittal Form
  - [ ] Fee Attached
- [ ] Amendment / Response
  - [ ] After Final
  - [ ] Affidavits/declaration(s)
- [ ] Extension of Time Request
- [ ] Express Abandonment Request
- [X] Information Disclosure Statement
- [ ] Certified Copy of Priority Document(s)
- [ ] Response to Missing Parts/ Incomplete Application
  - [ ] Response to Missing Parts under 37 CFR 1.52 or 1.53
- [ ] Assignment Papers (for an Application)
- [ ] Drawing(s)
- [ ] Licensing-related Papers
- [ ] Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- [ ] Petition to Convert to a Provisional Application
- [ ] Power of Attorney, Revocation Change of Correspondence Address
- [ ] Terminal Disclaimer
- [ ] Small Entity Statement
- [ ] Request for Refund
- [ ] After Allowance Communication to Group
- [ ] Appeal Communication to Board of Appeals and Interferences
- [ ] Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- [ ] Proprietary Information
- [ ] Status Letter
- [X] Additional Enclosure(s) (please identify below):

USPTO Form 1449; Cited References (35); receipt acknowledgment postcard

Authorization to Charge Deposit Account
Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Jonathan Alan Quine, Reg. No. 41,261, Quine Intellectual Property Law Group, P.C.
Signature	Jonathan Alan Quine
Date	January 27, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Amelia Weintraub		
Signature	Amelia Weintraub	Date	January 27, 2004

OIPE
FEB 0 2 2004
PATENT & TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on January 27, 2004

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By _____
Amelia Weintraub

Attorney Docket No. 26-000320US
Client Ref. No. NS210P2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	
Hong Jin, et al.	Examiner: Unassigned
Application No.: 10/672,302	Art Unit: 1648
Filed: September 26, 2003	
For: FUNCTIONAL MUTATIONS IN RESPIRATORY SYNCYTIAL VIRUS	INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97 and § 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jonathan Alan Quine, J.D., Ph.D.
Reg. No. 41,261

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known	
Application Number	**10/672,302**
Filing Date	**September 26, 2003**
First Named Inventor	**Hong Jin**
Group Art Unit	**1648**
Examiner Name	**Unassigned**
Attorney Docket Number	**26-000320US**
Date Submitted	**January 27, 2004**

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	01	5,922,326		Murphy et al.	07-13-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office	Foreign Patent Document Number	Foreign Patent Document Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	02	WO	02/44334	A2	Aviron, Inc.	06-06-2002		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	03	**Ahmadian** et al. (1999) Detection and characterization of proteins encoded by the second ORF of the M2 gene of pneumoviruses. J Gen Virol., 80:2011-2016.	
	04	**Ahmadian** et al. (2000) Expression of the ORF-2 protein of the human respiratory syncytial M2 gene is initiated by a ribosomal termination-dependent reinitiation mechanism. EMBO J., 19:2681-2689.	
	05	**Anderson** et al. (1985) Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol., 22:1050-1052.	
	06	**Asenjo** et al. (2000) Regulated but not constitutive human respiratory syncytial virus (HRSV) P protein phosphorylation is essential for oligomerization. FEBS Lett 467:279-284	
	07	**Barik** et al. (1995) Phosphorylation of Ser^{232} Directly Regulates the Transcriptional Activity of the P Protein of Human Respiratory Syncytial Virus: Phosphorylation of Ser^{237} May Play an Accessory Role. Virology 213:405-412	
	08	**Bermingham** et al. (1999) The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A, 96:11259-11264.	
	09	**Bukreyev** et al. (1996) Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol, 70:6634-6641.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC19
FEB 0 2 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	**10/672,302**
Filing Date	**September 26, 2003**
First Named Inventor	**Hong Jin**
Group Art Unit	**1648**
Examiner Name	**Unassigned**
Attorney Docket Number	**26-000320US**
Date Submitted	**January 27, 2004**

	10	**Caravokyri** et al. (1992) Assignment of mutant *ts*N19 (complementation group E) of respiratory syncytial virus to the P protein gene. J. Gen Virol. 73:865-873	
	11	**Cheng** et al. (2001) Chimeric Subgroup A Respiratory Syncytial Virus with the Glycoproteins Substituted by Those of Subgroup B and RSV without the M2-2 Gene are Attenuated in African Green Monkeys. Virology 283:59-68	
	12	**Cheng** et al. (2002) Expression of ß-galactosidase by recombinant respiratory syncytial viruses for microneutralization assay. J Virol Methods 105:287-96	
	13	**Collins** et al. (1985) The envelope-associated 22K protein of human respiratory syncytial virus: nucleotide sequence of the mRNA and a related polytranscript. J Virol, 54:65-71.	
	14	**Collins** et al. (1995) Production of infectious human respiratory syncytial virus from cloned cDNA confirms and essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. 92:11563-11567	
	15	**Dupuy** et al. (1999) Casein Kinase 2-Mediated Phosphorylation of Respiratory Synctial Virus Phosphoprotein P is Essential for the Transcription Elongation Activity of the Viral Polymerase; Phosphorylation by Casein Kinase 1 Occurs Mainly at Ser^{215} and is without Effect. J. Virol. 73:8384-8392	
	16	**Faulkner** et al. (1976) Respiratory Syncytial Virus *ts* Mutants and Nuclear Immunofluorescence. J. Virol. 20:487-500	
	17	**Garcia-Barreno** et al. (1996) Identification of Protein Regions Involved in the Interaction of Human Respiratory Syncytial Virus Phosphoprotein and Nucleoprtein: Significance for Nucleocapsid Assembly and Formation of Cytoplasmic Inclusions. J. Virol. 70:801-808	
	18	**Hardy** et al. (1998) The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol. 72: 520-526.	
	19	**Hardy** et al. (1999) Diverse Gene Functions of Respiratory Syncytial Virus Modulate the Efficiency of Transcription Termination and Respond Differently to M2-Mediated Antitermination. J Virol. 73: 170-176.	
	20	**Hardy** et al. (2000) The Cys_3-His_1 Motif of the Respiratory Syncytial Virus M2-1 Protein is Essential for Protein Function. J. Virol. 74: 5880-5885.	
	21	**Jin** et al. (1998) Recombinant Human Respiratory Syncytial Virus (RSV) from cDNA and Construction Subgroup A and B Chimeric RSV. Virology 251:206-214	
	22	**Jin** et al. (2000) Recombinant Respiratory Syncytial Viruses with Deletions in the NS1, NS2, SH, and M2-2 Genes are Attenuated *in Vitro* and *in Vivo.* Virology 273:210-218	
	23	**Jin** et al. (2000) Respiratory Syncytial Virus that Lacks Open Reading Frame 2 of the M2 Gene (m2-2) Has Altered Growth Characteristics and Is Attenuated in Rodents. J Virol 74:74-82	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC#37
FEB 0 2 2004

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	**10/672,302**
Filing Date	**September 26, 2003**
First Named Inventor	**Hong Jin**
Group Art Unit	**1648**
Examiner Name	**Unassigned**
Attorney Docket Number	**26-000320US**
Date Submitted	**January 27, 2004**

	24	**Jin** et al. (2003) Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21:3647-3652	
	25	**Khattar** et al. (2001) Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P and P-L interactions using a minigenome system. J. Gen Virol. 82:775-779	
	26	**Lu** et al. (2002) Identification of Temperature-Senstive Mutations in the Phosphoprotein of Respiratory Syncytial Virus that are Likely Involved in its Interaction with the Nucleoprotein. J. Virol. 76:2871-2880	
	27	**Lu** et al. (2002) The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro. J Virol. 76:10776-10784.	
	28	**Mallipeddi** et al. (1996) Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P interaction using a two-hybrid system. J. Gen Virol. 77:1019-1023	
	29	**Marriott** et al. (1999) A single Amino Acid Substitution in the Phosphoprotein of Respiratory Syncytial Virus Confers Thermosensivity in a Reconstituted RNA Polymerase System. J. Virol. 73:5162-5165	
	30	**Slack** et al. (1998) Characterization of the interaction of the human respiratory syncytial virus phosphoprotein and nucleocapsid protein using the two-hybrid system. Virus Research 55:167-176	
	31	**Tang** et al. (2001) Requirement of Cysteines and Length of the Human Respiratory Syncytial Virus M2-1 Protein for Protein Function and Virus Viability. J. Virol. 75:11328-11335	
	32	**Techaarpornkul** et al. (2001) Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol, 75:6825-6834.	
	33	**Teng** et al. (2000) Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol, 74:9317-9321.	
	34	**Whitehead** et al. (1998) A Single Nucleotide Substitution in the Transcription Start Signal of the M2 Gene of Respiratory Syncytial Virus Vaccine Candidate *cpts*248/404 is the Major Determinant of the Temperature-Senstitive and Attenuation Phenogypes. Virology 247:232-239	
	35	**Zhou** et al. (2003) Identification of amino acids that are critical to the processivity function of respiratory syncytial virus M2-1 protein. J Virol, 77:5046-5053.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.